Home » Newsletters » BioWorld Science

BioWorld Science

June 16, 2010

View Archived Issues

NeuroSearch claims new K(V)7 potassium channel activators

Novel autotaxin inhibitors identified by Merck KGaA

Alla Chem discloses new antiviral agents

Boehringer Ingelheim discovers new 5-HT2C receptor agonists

Mikana Therapeutics presents new protein kinase inhibitors

Long-term treatment compliance seen with Grazax vaccine tablet

JNJ-37822681 is safe and shows good D2 receptor occupancy in healthy men

BPA-directed antibody level in serum shows promise as biomarker for melanoma

Safety and preliminary antitumor activity of OSI-027 seen in ongoing first-in-man trial

Interim phase II data disclosed on PF-00299804 in recurrent/metastatic SCCHN

Novo Nordisk reports highlights of first quarter 2010

CF-102 shows anti-inflammatory and antitumor activity in vitro

Deferiprone reduces brain iron but does not lead to clinical improvement in PKAN

ViroStatics and Vichem Chemie collaborate on AV-HALTs for HIV/AIDS

Chiasma reports on phase I trial of oral octreotide acetate

FDA clears phase I/II alpha-1-antitrypsin trial in type 1 diabetes

PPD and Furiex complete spin-off of Furiex

Takeda launches Nesina, Unisia and Vectibix in Japan

Lundbeck to use Orasi Index to test effects of CNS drugs on human brain

EMA's COMP recommends orphan status for DR Cysteamine in cystinosis

Celsion to report on phase I/II DIGNITY trial in recurrent chest wall breast cancer

Amylin, Lilly and Alkermes report on DURATION-4 trial of Bydureon

Scancell begins dosing in phase I trial of SCIB-1 in melanoma

Stealth Peptides' phase I Bendavia trial progresses

COMP recommends orphan drug status for 2B3-101 in glioma

Otonomy secures funds to advance OTO-104 and OTO-203

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...